Remote research study to develop measurement technologies
The goal is to develop measurement technologies that can help improve clinical trials for ataxias.
About the Study
Eligible Ataxia Types
Spinocerebellar Ataxias and Multiple System Atrophy
Type of Study
Research Study
Clinical Trial Phase
N/A
Age Range
Adult 18+
Study Start Date
11/2020
Estimated Completion Date
N/A – Ongoing
IRB Approval #
2019P003458
Location(s)
Massachusetts General Hospital
Remote Study
Contact Information
Study Coordinator
mghremotescastudy@mgb.org
Phone: 617-726-7909
What does participation in the study entail?
No in-person visits are necessary. Participants will be asked to wear a wrist and ankle device continuously for one week, complete a speech survey and a computer mouse task twice per week for 2 weeks, and complete quality of life surveys. Participants will be asked to complete similar study tasks every 6 months for up to 3 years.
What are the potential benefits for participants?
This study will help develop measurement tools to improve clinical trials in ataxias.
What are the potential risks for participants?
As with all studies conducted online, there is a potential for a security breach of collected data and confidentially, but we take any and all precautions to protect collected data.
Is there financial compensation?
Yes. $50-$300. Participants will receive $50 for each time they participate in the study.
Is there travel reimbursement?
No
Who is eligible?
Adults who have been diagnosed with spinocerebellar ataxia, have a family history of ataxia, multiple system atrophy, or healthy volunteers. You are eligible to participate even if you do not have any symptoms. We want to develop tools that can detect and measure the earliest signs of ataxia. We prioritize recruiting individuals who can ambulate without assistive walking devices.
Other Information
View Other Research Opportunities
Spinocerebellar Ataxia Patient Feedback Survey
The survey aims to gather opinions about Antisense Oligonucleotide (ASO) therapy research, and the information gathered will be used to help develop future clinical studies for ataxia. Link to Enroll: Read More…
PATH
Proactive Approaches to Health for Asymptomatic Adults at Risk for Neurodegenerative Conditions The aim of this study is to assess the needs of asymptomatic adults at-risk to carry a pathogenic Read More…
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy (CYPRESS)
This is a Phase 3, multi-center, randomized withdrawal study to evaluate the efficacy and durability of ampreloxetine in participants with MSA and symptomatic nOH after 20 weeks of treatment. This Read More…
